Discovery of N -Alkyl Piperazine Side Chain Based CXCR4 Antagonists with Improved Drug-like Properties.

A novel series of CXCR4 antagonists with piperidinyl and piperazinyl alkylamine side chains designed as butyl amine replacements are described. Several of these compounds showed similar activity to the parent compound TIQ-15 () in a SDF-1 induced calcium flux assay. Preliminary structure-activity relationship investigations led us to identify a series containing -propyl piperazine side chain analogs exemplified by with improved off-target effects as measured in a muscarinic acetylcholine receptor (mAChR) calcium flux assay and in a limited drug safety panel screen. Further efforts to explore SAR and optimize drug properties led to the identification of the '-ethyl--propyl-piperazine tetrahydroisoquinoline derivative and the -propyl-piperazine benzimidazole compound , which gave the best overall profiles with no mAChR or CYP450 inhibition, good permeability in PAMPA assays, and metabolic stability in human liver microsomes.